| 来源类型 | Testimony
|
| 规范类型 | 其他
|
| Testimony on HR 3 and Other Drug Pricing Reforms |
| Benedic N. Ippolito
|
| 发表日期 | 2019-09-26
|
| 出版年 | 2019
|
| 语种 | 英语
|
| 摘要 | Subcommittee Chairwoman Eshoo, Subcommittee Ranking Member Burgess, Chairman Pallone, Ranking Member Walden, and members of the Committee, thank you for the opportunity to testify today on efforts to reduce the financial burden of prescription drugs. My name is Benedic Ippolito—I am an economist and research fellow at the American Enterprise Institute. Prescription drugs can offer tremendous benefit to Americans, but they can also represent major financial burdens to patients. Indeed, Americans regularly list reducing prescription drug prices as one of their top policy priorities.
So, I am glad that this Committee, and others in both chambers, are considering this issue so seriously. In my testimony I will focus on two elements of recent proposals: Redesigning the Medicare prescription drug benefit, known as Medicare Part D, and allowing for the Secretary of Health and Human Services (HHS) to negotiate drug prices.
Read the full testimony here: |
| 主题 | Health Economics
|
| 标签 | Health care costs
; health spending
; Medicare
|
| URL | https://www.aei.org/research-products/testimony/testimony-on-hr-3-and-other-drug-pricing-reforms/
|
| 来源智库 | American Enterprise Institute (United States)
|
| 资源类型 | 智库出版物
|
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/209917
|
推荐引用方式
GB/T 7714 |
Benedic N. Ippolito. Testimony on HR 3 and Other Drug Pricing Reforms. 2019.
|
|
文件名：
|
Ippolito_DrugPricing_EC_Sept2019-1.pdf
|
|
格式：
|
Adobe PDF
|
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
